Loading…
Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors
Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six e...
Saved in:
Published in: | Neurological sciences and neurophysiology 2020-07, Vol.37 (3), p.118-123 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63 |
container_end_page | 123 |
container_issue | 3 |
container_start_page | 118 |
container_title | Neurological sciences and neurophysiology |
container_volume | 37 |
creator | Erdag, Ece Şahin-Özkartal, Ceren Küçükali, Cem Arıcıoğlu, Feyza Tüzün, Erdem |
description | Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P < 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required. |
doi_str_mv | 10.4103/NSN.NSN_2_20 |
format | article |
fullrecord | <record><control><sourceid>wolterskluwer_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6ea8f20255e14240b546c2307ea3bb19</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6ea8f20255e14240b546c2307ea3bb19</doaj_id><sourcerecordid>10.4103/NSN.NSN_2_20_118_Serum immunogl</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63</originalsourceid><addsrcrecordid>eNptkUtOwzAQQCMEEgjYcQDv2BDwJ3bcJX8qVbAAJHaW7UzA4MSVnbRwIg7CxUhbiliwGM1oPk8avSw7IPi4IJid3N7fHg-hqKJ4I9uhgolcCv60-afezvZTesUYU8xGQvCd7P0eYt8g1zR9G559ML13LbpGoUYt9DHkZ_Dy9QndYUIXLoFOgKa6c9B2CUWoegvIQgQTtUfwPo2Qkgst8jADnxaU1MeZmw3T4exlrj9QrW0XYtrLtmrtE-z_5N3s8ery4fwmn9xdj89PJ7llvPS50cZURgppq4KJETFyeJZjMJIwjqW1JTOWybouqSEaqhGpC8wEEbYsCl4JtpuNV9wq6Fc1ja7R8UMF7dSyEeKz0rFz1oMSoGVNMeUcSEELbHghLGW4BM2MIaOBdbRi2RhSilD_8ghWCwlqIWAtYVi_WK3Pg-8gpjffzyGqBqq3Nsz_vVGESLVUotZK2DeTmpWi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</title><source>DOAJ Directory of Open Access Journals</source><creator>Erdag, Ece ; Şahin-Özkartal, Ceren ; Küçükali, Cem ; Arıcıoğlu, Feyza ; Tüzün, Erdem</creator><creatorcontrib>Erdag, Ece ; Şahin-Özkartal, Ceren ; Küçükali, Cem ; Arıcıoğlu, Feyza ; Tüzün, Erdem</creatorcontrib><description>Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P < 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.</description><identifier>ISSN: 2636-865X</identifier><identifier>EISSN: 2636-865X</identifier><identifier>DOI: 10.4103/NSN.NSN_2_20</identifier><language>eng</language><publisher>Wolters Kluwer India Pvt. Ltd</publisher><subject>akt pathway ; behçet's disease ; immunoglobulin g ; inflammation ; neuro-behçet's disease</subject><ispartof>Neurological sciences and neurophysiology, 2020-07, Vol.37 (3), p.118-123</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,2102,27924,27925</link.rule.ids></links><search><creatorcontrib>Erdag, Ece</creatorcontrib><creatorcontrib>Şahin-Özkartal, Ceren</creatorcontrib><creatorcontrib>Küçükali, Cem</creatorcontrib><creatorcontrib>Arıcıoğlu, Feyza</creatorcontrib><creatorcontrib>Tüzün, Erdem</creatorcontrib><title>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</title><title>Neurological sciences and neurophysiology</title><description>Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P < 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.</description><subject>akt pathway</subject><subject>behçet's disease</subject><subject>immunoglobulin g</subject><subject>inflammation</subject><subject>neuro-behçet's disease</subject><issn>2636-865X</issn><issn>2636-865X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkUtOwzAQQCMEEgjYcQDv2BDwJ3bcJX8qVbAAJHaW7UzA4MSVnbRwIg7CxUhbiliwGM1oPk8avSw7IPi4IJid3N7fHg-hqKJ4I9uhgolcCv60-afezvZTesUYU8xGQvCd7P0eYt8g1zR9G559ML13LbpGoUYt9DHkZ_Dy9QndYUIXLoFOgKa6c9B2CUWoegvIQgQTtUfwPo2Qkgst8jADnxaU1MeZmw3T4exlrj9QrW0XYtrLtmrtE-z_5N3s8ery4fwmn9xdj89PJ7llvPS50cZURgppq4KJETFyeJZjMJIwjqW1JTOWybouqSEaqhGpC8wEEbYsCl4JtpuNV9wq6Fc1ja7R8UMF7dSyEeKz0rFz1oMSoGVNMeUcSEELbHghLGW4BM2MIaOBdbRi2RhSilD_8ghWCwlqIWAtYVi_WK3Pg-8gpjffzyGqBqq3Nsz_vVGESLVUotZK2DeTmpWi</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Erdag, Ece</creator><creator>Şahin-Özkartal, Ceren</creator><creator>Küçükali, Cem</creator><creator>Arıcıoğlu, Feyza</creator><creator>Tüzün, Erdem</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20200701</creationdate><title>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</title><author>Erdag, Ece ; Şahin-Özkartal, Ceren ; Küçükali, Cem ; Arıcıoğlu, Feyza ; Tüzün, Erdem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>akt pathway</topic><topic>behçet's disease</topic><topic>immunoglobulin g</topic><topic>inflammation</topic><topic>neuro-behçet's disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erdag, Ece</creatorcontrib><creatorcontrib>Şahin-Özkartal, Ceren</creatorcontrib><creatorcontrib>Küçükali, Cem</creatorcontrib><creatorcontrib>Arıcıoğlu, Feyza</creatorcontrib><creatorcontrib>Tüzün, Erdem</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Neurological sciences and neurophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erdag, Ece</au><au>Şahin-Özkartal, Ceren</au><au>Küçükali, Cem</au><au>Arıcıoğlu, Feyza</au><au>Tüzün, Erdem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors</atitle><jtitle>Neurological sciences and neurophysiology</jtitle><date>2020-07-01</date><risdate>2020</risdate><volume>37</volume><issue>3</issue><spage>118</spage><epage>123</epage><pages>118-123</pages><issn>2636-865X</issn><eissn>2636-865X</eissn><abstract>Objective: Anti-neuronal antibodies are found in sera of neuro-Behçet's disease (NBD) patients. In this study, our aim was to analyze the potential mechanisms by which NBD immunoglobulin (Ig) Gs affect neuronal dysfunction. Materials and Methods: Purified IgGs obtained from pooled sera of six each NBD patients and healthy controls (HCs) were administered to Sprague Dawley rats through intraventricular injection. Control rats received phosphate-buffered saline (PBS) only. Locomotor activity was assessed by open field test on days 0, 10, and 25. Cerebral expression levels of intracellular pathway factors associated with cell survival and viability were measured by real-time polymerase chain reaction. Results: Rats treated with NBD IgG exhibited reduced motor activity. On day 25, the mean number of crossings was 44 ± 7, 90 ± 12, and 93 ± 5 and the mean number of rearings was 18 ± 7, 34 ± 5, and 35 ± 6 for NBD IgG, HC IgG, and PBS groups, respectively (P < 0.001). Relative expression levels of Akt-1 (0.4 ± 0.2, 1.0 ± 0.3, and 0.9 ± 0.6; P = 0.004), DJ-1 (0.6 ± 0.2, 1.0 ± 0.6, and 0.9 ± 0.5; P = 0.047), mouse double mininute-2 (0.5 ± 0.3, 0.9 ± 0.2, and 1.0 ± 0.2; P = 0.002), and mechanistic target of rapamycin (0.4 ± 0.2, 0.8 ± 0.4, and 0.9 ± 0.6; P = 0.006) were significantly lower in NBD-IgG group than HC IgG and PBS groups. By contrast, the expression levels of factors associated with apoptosis (caspase 3, mitochondrial carrier homolog 1, and B-cell lymphoma-2) were comparable among different treatment arms. Conclusion: Our results suggest that at least a fraction of NBD IgG interacts with neuronal surface antigens and subsequently decreases neuronal viability through Akt pathway inhibition. By contrast, NBD IgG does not appear to activate neuronal apoptosis. Further identification of the binding sites of serum IgG ıs required.</abstract><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/NSN.NSN_2_20</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2636-865X |
ispartof | Neurological sciences and neurophysiology, 2020-07, Vol.37 (3), p.118-123 |
issn | 2636-865X 2636-865X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_6ea8f20255e14240b546c2307ea3bb19 |
source | DOAJ Directory of Open Access Journals |
subjects | akt pathway behçet's disease immunoglobulin g inflammation neuro-behçet's disease |
title | Serum immunoglobulin G of neuro-Behçet's Disease patients reduce cerebral expression levels of survival pathway factors |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T16%3A14%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20immunoglobulin%20G%20of%20neuro-Beh%C3%A7et's%20Disease%20patients%20reduce%20cerebral%20expression%20levels%20of%20survival%20pathway%20factors&rft.jtitle=Neurological%20sciences%20and%20neurophysiology&rft.au=Erdag,%20Ece&rft.date=2020-07-01&rft.volume=37&rft.issue=3&rft.spage=118&rft.epage=123&rft.pages=118-123&rft.issn=2636-865X&rft.eissn=2636-865X&rft_id=info:doi/10.4103/NSN.NSN_2_20&rft_dat=%3Cwolterskluwer_doaj_%3E10.4103/NSN.NSN_2_20_118_Serum%20immunogl%3C/wolterskluwer_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c357l-babbdb868cd43691b841050eb813508cc73bc38ff72b1aed91f403616c7445d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |